- Ruxolitinib plus photopheresis works faster and better than photopheresis alone
- Helps patients struggling with chronic graft-versus-host disease after transplants
- Not yet standard care — still under study, but results are promising
This combo may help patients reduce or stop steroid use — a major win for quality of life.
After a bone marrow transplant, many patients hope for a fresh start. But for some, the new immune system turns against their body. It causes dry eyes, rashes, stiff joints, and trouble breathing. This condition is called chronic graft-versus-host disease, or cGvHD. It can last for years. And treating it often means high-dose steroids — which come with serious side effects.
Doctors need better tools. Now, a new study suggests a powerful one-two punch may offer real relief.
cGvHD affects up to 70% of people who get a donor stem cell transplant. That’s over 20,000 patients worldwide each year. The immune system, meant to protect, starts attacking the skin, eyes, liver, lungs, and gut. Patients may lose the ability to work, eat, or even open their hands.
Steroids are the first treatment. But many patients don’t improve — or they depend on steroids long-term. That can lead to diabetes, weak bones, infections, and weight gain. So doctors look for other options.
One is a drug called ruxolitinib (RUX). Another is a blood treatment called extracorporeal photopheresis (ECP). Both are used when steroids fail. But until now, we didn’t know if using them together works better than ECP alone.
The surprising shift
For years, doctors treated cGvHD step by step. One drug at a time. The idea was to avoid too many side effects. So combining treatments wasn’t common.
But here’s the twist: the body’s immune attack in cGvHD is complex. One drug may not be enough to calm it.
What’s different this time? Researchers tried hitting the immune system in two ways at once — with RUX and ECP together.
Think of the immune system like a car. In cGvHD, the engine is stuck in high gear. Steroids try to slow it down. But sometimes, the brakes don’t work well.
Ruxolitinib acts like a brake on immune signals. It blocks a pathway called JAK, which revs up inflammation.
ECP is different. It’s like retraining the driver. Blood is taken out, treated with light and a special drug, then returned. This teaches immune cells to stop attacking the body.
Together, they may calm the system faster — and more completely.
The study looked at 51 patients with steroid-resistant or steroid-dependent cGvHD. Thirty got RUX plus ECP. Twenty-one got ECP alone. All were treated at one center between 2012 and 2025. Most had tried other treatments first.
The big news? More patients improved when they got both treatments.
77% responded to RUX-ECP. Only 52% responded to ECP alone. That’s a big difference — though not quite strong enough to rule out chance.
But the speed of response was clear. Patients on the combo saw improvement in just 2.6 months. Those on ECP alone waited over a year — 12.3 months — for the same result.
Even better: steroid use dropped sharply with the combo. At one year, 69% of combo patients stopped steroids completely. Only 10% did on ECP alone. And 88% cut their dose — compared to just 30% in the other group.
This doesn’t mean this treatment is available yet.
But there’s a catch.
The study was small. And it wasn’t a randomized trial — patients weren’t assigned by chance. Doctors chose the treatment based on their judgment. That can skew results.
Also, both groups had similar survival and cancer relapse rates. So the combo didn’t harm patients — but it didn’t extend life either. Its real benefit is in quality of life.
What scientists didn’t expect
Experts thought combining treatments might increase side effects. But that didn’t happen. The combo was as safe as ECP alone. Most side effects were from ruxolitinib — like low blood counts or infections — and were manageable.
Some patients even stopped the combo after a year, once their symptoms stayed under control. That’s rare in cGvHD.
If you or a loved one has cGvHD and struggles with steroids, this combo may be worth discussing with your doctor. It’s not approved as a standard first combo — yet. But some centers are already using it.
Don’t stop or change treatment on your own. But do ask: Could this two-pronged approach help me?
The risks remain
This was one center’s experience. Only 51 patients. Most had mild to moderate cGvHD. Results might differ in sicker patients or at other hospitals. Also, the study looked back at records — not a controlled trial. So we can’t say for sure the combo caused the better results.
What happens next
Larger, randomized trials are needed. Researchers must confirm these results across centers. If they do, this combo could become a new standard for cGvHD.
For now, it offers real hope. Not a cure. But a faster path to feeling better — and living without steroids.
